

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(stock code: 2552)**

## **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Hua Medicine (the “**Company**”) announces that on March 17, 2022, the Company granted share options (the “**Share Options**”) to employees of the Company (the “**Grantee**”) pursuant to the Company’s share option scheme which was conditionally approved and adopted on August 26, 2018 and effective beginning September 14, 2018, subject to acceptance by the Grantee. The Share Options entitle the Grantee to subscribe for a total of 8,700,000 new shares with a nominal value of US\$0.001 each (the “**Shares**”) in the share capital of the Company.

Details of the Share Options granted are as follows:

Date of the Grant: March 17, 2022

Exercise price of Share Options granted: HK\$3.400 per Share, which is the highest of:

- i. the closing price of HK\$3.400 per Share as stated in the daily quotation sheets issued by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on the date of grant of the Share Options;
- ii. the average closing price of HK\$2.784 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the date of grant of the Share Options; and
- iii. the nominal value of US\$0.001 per Share.

Number of Share Options granted: 8,700,000 (each Share Option shall entitle the holder thereof to subscribe for one (1) Share).

Validity period of the Share Options: Ten (10) years from the date of grant.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, except for Dr. Li Chen (executive Director and chief executive officer of the Company) who has been granted 5,000,000 Share Options, none of the other Grantees are a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them. The grant of Share Options to Dr. Li Chen has been approved by the independent non-executive Directors of the Company.

By Order of the Board  
**DR. LI CHEN**  
*Chief Executive Officer and  
Executive Director*

Hong Kong, March 17, 2022

*As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Ms. Zhao Wei as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.*